APRINOIA Therapeutics

company

About

Biotechnology, Neuorscience

  • 51 - 100

Details

Last Funding Type
Series B
Last Funding Money Raised
$11.10M
Industries
Biotechnology,Health Diagnostics,Medical,Therapeutics
Founded date
May 20, 2015
Number Of Employee
51 - 100
Operating Status
Active

APRINOIA is a late-stage biotechnology company committed to protecting patients' brain health and changing outcomes of neurodegenerative diseases through first-in-class and best-in-class diagnostic tools and novel therapies. The company aims to bring precision medicine to neuroscience by identifying and targeting the protein aggregates of tau, alpha-synuclein and other proteins that play a critical role in the pathogenesis of many neurodegenerative diseases, such as Alzheimer's and Parkinson's Diseases. The company currently has operations in Hong Kong, Suzhou, Shanghai, Tokyo, and Boston.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$11.10M
APRINOIA Therapeutics has raised a total of $11.10M in funding over 2 rounds. Their latest funding was raised on Jan 16, 2018 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 16, 2018 Series B $11.10M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
APRINOIA Therapeutics is funded by 1 investors. TaiAn Technologies are the most recent investors.
Investor Name Lead Investor Funding Round
TaiAn Technologies Series B